Stock comparison
IDEXX Laboratories
Theravance Biopharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
TBPH
Theravance Biopharma
Market cap
$843.92M
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TBPH | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 53D | IDXX |
| Benjamin Graham | 80A | 51D | IDXX |
| Philip Fisher | 75B | 45D | IDXX |
| Peter Lynch | 71B | 53C | IDXX |
| Joel Greenblatt | 83C | 36D | IDXX |
| Charlie Munger | 87A | 39D | IDXX |
| Terry Smith | 84A | 56C | IDXX |
Side-by-side metrics
| Metric | IDXX | TBPH |
|---|---|---|
| Market cap | $44.12B | $843.92M |
| P/E (TTM) | 39.0x | 7.4x |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -1.32% |
| Gross margin | 62.05% | 104.1% |
| Net margin | 24.63% | 104.34% |
| Revenue CAGR 5y | 7.56% | 18.06% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs -1.32%+103%
- Market cap$44.12Bvs $843.92M+98%
TBPH leads on
- EV/EBIT-vs 31.6x+166%
- P/E (TTM)7.4xvs 39.0x+81%
- Net margin104.34%vs 24.63%+76%
- Debt / Equity0.3xvs 0.7x+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.